DRMref Logo

Home

Download

Statistics

Landscape

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Datasets with differential expression of this gene

leaf

Expression of this gene in the resistant group across all datasets and cell types

leaf

Significant ligand-receptor pairs related to this gene (This gene does not contain this module)

leaf

Known drug resistance mechanisms of this gene (This gene does not contain this module)

leaf

MicroRNAs (miRNAs) regulating this gene

leaf

Motifs and transcription factors (TFs) regulating this gene

leaf

Acts as a transcription factor (This gene does not contain this module)

leaf

Acts as a drug target

Gene: VCAN

Summary for VCAN

Gene informationGene symbol

VCAN

Ensembl ID

ENSG00000038427

Entrez ID

1462

Gene nameversican
SynonymsCSPG2|PG-M
Gene typeprotein_coding
UniProtAcc

P13611


Top

Dataset with differentially expressed gene: VCAN

check buttonDifferentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.
DatasetSourceTissueCancer type level1Cancer type level2Drug typeRegimenTimepointCell typeavg_log2FCp_val_adj

GSE169246_PacBlood

patientsPeripheral blood mononuclear cellsBreast cancerAdvanced triple-negative breast cancer (TNBC)ChemotherapypaclitaxelpreMono/Macro0.4539280.00e+00

GSE169246_PacBlood

patientsPeripheral blood mononuclear cellsBreast cancerAdvanced triple-negative breast cancer (TNBC)ChemotherapypaclitaxelprecDCs0.5487344.24e-06

GSE169246_PacAteBlood

patientsPeripheral blood mononuclear cellsBreast cancerAdvanced triple-negative breast cancer (TNBC)Immunotherapyatezolizumab + paclitaxelprecDCs0.5931649.29e-07

GSE169246_PacAteBlood

patientsPeripheral blood mononuclear cellsBreast cancerAdvanced triple-negative breast cancer (TNBC)Immunotherapyatezolizumab + paclitaxelpreMono/Macro0.9044030.00e+00

GSE197268_Axi-cel

patientsPeripheral blood mononuclear cellsAcute lymphoblastic leukemiaLarge B-cell acute lymphoblastic leukemia (B-ALL)Immunotherapyaxi-cel (CAR-T)postMono/Macro-0.2517580.00e+00

GSE197268_Axi-cel

patientsPeripheral blood mononuclear cellsAcute lymphoblastic leukemiaLarge B-cell acute lymphoblastic leukemia (B-ALL)Immunotherapyaxi-cel (CAR-T)preMono/Macro0.5548760.00e+00

GSE164551

patientsBone marrow aspirateMultiple myelomaRefractory multiple myeloma (MM)ImmunotherapyCAR-TNAMono/Macro-0.415573.04e-18

GSE212217

patientsPeripheral blood mononuclear cellsEndometrial cancerEpigenetic MMRd endometrial carcinomaImmunotherapypembrolizumabpostMono/Macro0.304367.70e-36

GSE212217

patientsPeripheral blood mononuclear cellsEndometrial cancerEpigenetic MMRd endometrial carcinomaImmunotherapypembrolizumabpreMono/Macro0.3074430.00e+00

GSE197268_Tisa-cel

patientsPeripheral blood mononuclear cellsAcute lymphoblastic leukemiaLarge B-cell acute lymphoblastic leukemia (B-ALL)Immunotherapytisa-cel (CAR-T)postMono/Macro-0.2979760.00e+00

GSE197268_Tisa-cel

patientsPeripheral blood mononuclear cellsAcute lymphoblastic leukemiaLarge B-cell acute lymphoblastic leukemia (B-ALL)Immunotherapytisa-cel (CAR-T)preMono/Macro1.218510.00e+00

GSE161801_PI

patientsBone marrow aspirateMultiple myelomaRefractory multiple myeloma (MM)Targeted therapycarfilzomib + dexamethasonepostMono/Macro-0.3654771.21e-12

GSE162117

patientsPeripheral blood mononuclear cellsAcute myeloid leukemiaTefractory acute myeloid leukemia (AML)Targeted therapyficlatuzumabpostcDCs-0.454211.75e-24

GSE162117

patientsPeripheral blood mononuclear cellsAcute myeloid leukemiaTefractory acute myeloid leukemia (AML)Targeted therapyficlatuzumabpostMalignant cells-0.4115120.00e+00

GSE162117

patientsPeripheral blood mononuclear cellsAcute myeloid leukemiaTefractory acute myeloid leukemia (AML)Targeted therapyficlatuzumabpreMalignant cells-0.6939780.00e+00

GSE199333

patientsBone marrow aspirateAcute myeloid leukemiaPrimary FLT3-ITD-mutated acute myeloid leukemia (AML)Targeted therapygilteritinibpostMalignant cells-0.9462710.00e+00

GSE131984_JQ1Pal

SUM159 cell lineCell lineBreast cancerTriple-negative breast cancer (TNBC)Targeted therapyJQ1 + palbociclibNAMalignant cells0.3772769.15e-14

GSE131984_Pal

SUM159 cell lineCell lineBreast cancerTriple-negative breast cancer (TNBC)Targeted therapypalbociclibNAMalignant cells0.4892944.92e-28

GSE175716

PDXTumor tissueLiver cancerAdvanced hepatocellular carcinomaTargeted therapysorafenibNAMalignant cells-0.8412850.00e+00

Top

Expression of VCAN in the resistant group across all datasets and cell types

check buttonRed dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)
boxplot

Top

Significant ligand-receptor pairs related to VCAN

check buttonThis table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

check buttonThis table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating VCAN

check buttonThis table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)
Gene symbolmiRNAScoreGeneBank accession
VCANhsa-miR-569699.1738NM_001126336
VCANhsa-miR-455-5p95.2286NM_001126336
VCANhsa-miR-6846-3p94.8027NM_001126336
VCANhsa-miR-23c94.7516NM_001126336
VCANhsa-miR-23a-3p94.7516NM_001126336
VCANhsa-miR-23b-3p94.7516NM_001126336
VCANhsa-miR-361293.5456NM_001126336
VCANhsa-miR-317593.0151NM_001126336
VCANhsa-miR-1213692.7805NM_001126336
VCANhsa-miR-65092.7551NM_001126336
VCANhsa-miR-141-3p92.5078NM_001126336
VCANhsa-miR-200a-3p92.5078NM_001126336
VCANhsa-miR-524-5p92.429NM_001126336
VCANhsa-miR-520d-5p92.429NM_001126336
VCANhsa-miR-6849-3p92.112NM_001126336
VCANhsa-miR-128991.4671NM_001126336
VCANhsa-miR-9-5p91.0038NM_001126336
VCANhsa-miR-6512-3p90.9344NM_001126336
VCANhsa-miR-6720-5p90.9344NM_001126336
VCANhsa-miR-33a-5p90.7917NM_001126336
VCANhsa-miR-33b-5p90.7917NM_001126336
VCANhsa-miR-442490.4933NM_001126336
VCANhsa-miR-472990.463NM_001126336
VCANhsa-miR-1250-3p88.7807NM_001126336
VCANhsa-miR-122b-5p88.0289NM_001126336
VCANhsa-miR-6777-3p87.8092NM_001126336
VCANhsa-miR-430986.672NM_001126336
VCANhsa-miR-4760-5p86.5283NM_001126336
VCANhsa-miR-431185.5503NM_001126336
VCANhsa-miR-3121-3p85.2408NM_001126336
VCANhsa-miR-6792-3p85.0516NM_001126336
VCANhsa-miR-5011-5p84.9407NM_001126336
VCANhsa-miR-335-3p84.5695NM_001126336
VCANhsa-miR-319884.1946NM_001126336
VCANhsa-miR-10783.8037NM_001126336
VCANhsa-miR-103a-3p83.8037NM_001126336
VCANhsa-miR-135b-5p83.7127NM_001126336
VCANhsa-miR-3150a-3p83.6958NM_001126336
VCANhsa-miR-6763-5p83.6958NM_001126336
VCANhsa-miR-6842-3p83.3991NM_001126336
VCANhsa-miR-806183.292NM_001126336
VCANhsa-miR-135a-5p81.4201NM_001126336
VCANhsa-miR-808381.2399NM_001126336
VCANhsa-miR-4691-5p80.8095NM_001126336
VCANhsa-miR-223-5p80.1562NM_001126336
Page: 1

Top

Motifs and transcription factors (TFs) regulating VCAN

check buttonThis table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)
Gene symbolmotifTF_highConf
VCANtaipale_tf_pairs__ETV5_HES7_NNCACGTGNNNNCCGGAANN_CAPETV5; HES7 (directAnnotation).
VCANmetacluster_144.13HIC1; HIC1 (directAnnotation).
VCANtransfac_pro__M00665SP3 (directAnnotation).
VCANtaipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNNNNNNCGGAAGN_CAP_reprE2F1; ELK1 (directAnnotation).
VCANtransfac_pro__M02898SMAD3 (directAnnotation).
VCANkznf__ZNF548_Imbeault2017_OM_RCADEZNF548 (directAnnotation).
VCANtaipale_tf_pairs__GCM1_SPDEF_RTGNKGGCGGAWG_CAP_reprGCM1; SPDEF (directAnnotation).
VCANhocomoco__ZFP57_MOUSE.H11MO.0.BZFP57 (inferredBy_Orthology).
VCANtaipale_tf_pairs__TFAP2C_HES7_NNCRCGYGNNNNNNSCCNNNGGS_CAP_reprHES7; TFAP2C (directAnnotation).
VCANtransfac_pro__M07329SP7 (directAnnotation).
VCANtaipale_cyt_meth__E2F2_NCGCGCGCGCM_eDBD_methE2F2 (directAnnotation).
VCANmetacluster_126.4ZNF12; ZNF12; ZNF44; ZNF563; ZNF93 (directAnnotation).
VCANjaspar__MA0079.5SP1 (directAnnotation).
VCANkznf__KLF1_Barrera2016.2_PBMKLF1 (directAnnotation).
VCANcisbp__M07938E2F1 (directAnnotation).
VCANtransfac_pro__M07260IKZF1 (directAnnotation).
VCANtransfac_pro__M01835KLF4 (directAnnotation).
VCANhocomoco__PATZ1_HUMAN.H11MO.1.CPATZ1 (directAnnotation).
VCANswissregulon__hs__MTA3MTA3 (directAnnotation).
VCANmetacluster_52.10GTF3C2; ZNF436 (directAnnotation).
VCANtaipale_tf_pairs__FLI1_CEBPD_RNCGGANNTTGCGCAAN_CAPCEBPD; FLI1 (directAnnotation).
VCANtransfac_pro__M04886ETS1 (directAnnotation).
VCANtaipale_tf_pairs__GCM1_MAX_NNCACGTGNNNGCGGGYN_CAP_reprGCM1; MAX (directAnnotation).
VCANtransfac_pro__M06800ZBTB22 (inferredBy_Orthology).
VCANmetacluster_29.6ZNF436 (directAnnotation).
VCANmetacluster_187.8ZNF22 (directAnnotation).
VCANtfdimers__MD00035MZF1; STAT6 (directAnnotation).
VCANtransfac_pro__M05798ZNF517 (directAnnotation).
VCANtransfac_pro__M06257ZNF616 (directAnnotation).
VCANtransfac_pro__M05972ZNF701 (directAnnotation).
VCANtransfac_pro__M05945ZNF300 (directAnnotation).
VCANtransfac_pro__M05908ZNF319 (inferredBy_Orthology).
VCANtransfac_pro__M06564ZNF578 (directAnnotation).
VCANtfdimers__MD00029IKZF2; NKX3-2 (directAnnotation).
VCANmetacluster_113.5OVOL1; OVOL1; OVOL2; OVOL2; OVOL2; OVOL2 (directAnnotation). OVOL1; OVOL1; OVOL1 (inferredBy_Orthology).
VCANkznf__ZNF334_Imbeault2017_OM_MEMEZNF334 (directAnnotation).
VCANtransfac_public__M00208NFKB1; RELA (directAnnotation).
VCANtransfac_pro__M06072ZNF623 (directAnnotation).
VCANtransfac_pro__M06939ZBTB11 (directAnnotation).
VCANtfdimers__MD00352ILF2; MYCN; NFATC2 (directAnnotation).
VCANtransfac_pro__M06629ZNF578 (directAnnotation).
VCANtransfac_pro__M04706RELA (directAnnotation).
VCANtaipale_tf_pairs__HOXD12_ELK3_RSCGGAAGTCGTAAAN_CAPELK3; HOXD12 (directAnnotation).
VCANmetacluster_5.1HIVEP1; HIVEP1; NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; NFKB2; NFKB2; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELB; RELB (directAnnotation). NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; REL; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELB; RELB; RELB (inferredBy_Orthology).
VCANswissregulon__mm__Atf2ATF2 (inferredBy_Orthology).
VCANhdpi__GTF3C2GTF3C2 (directAnnotation).
VCANhdpi__FEZF2FEZF2 (directAnnotation).
VCANtransfac_pro__M06331ZNF343 (directAnnotation).
VCANkznf__ZNF441_Imbeault2017_RP_RCADEZNF441 (directAnnotation).
VCANhdpi__NRLNRL (directAnnotation).
Page: 1 2 3 4 5

Top

Acts as a transcription factor

check buttonThis table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

check buttonThis table shows that this differential gene acts as a drug target.
Target nameDrug nameDrug IDDrug type
VCAN"Hyaluronic acid"

DB08818

small molecule
Page: 1




1"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."